Jennifer S. Buell: Breaking Barriers in Advanced Sarcoma Treatment
Jennifer S. Buell, President and Chief Executive Officer at MiNK Therapeutics, shared an article by Breelyn A. Wilky, et al. on LinkedIn:
“Breaking Barriers in Advanced Sarcoma Treatment.
Advanced sarcomas are notoriously challenging, with poor outcomes and limited treatment options. A newly published study in the Journal of Clinical Oncology highlights the potential of combining botensilimab (BOT), an Fc-enhanced anti–CTLA-4 antibody, with balstilimab (BAL), an anti–PD-1 antibody, to address this critical unmet need. The combination demonstrated an ORR of 19.2% across all sarcomas and 27.8% in angiosarcoma, with particularly strong responses in visceral (33.3%) and cutaneous (22.2%) subtypes.
Notably, the responses were durable, with a median DOR of 21.7 months, and the safety profile was manageable, with no grade 4 or 5 treatment-related adverse events.
These results bring hope to patients and families facing this aggressive disease and underscore the importance of pursuing innovative approaches in oncology.
Congratulations Breelyn Wilky, Michael Gordon, Jon Trent, Anthony El-khoueiry, Andrea Bullock, Apostolia M Tsimberidou, et al. behind this groundbreaking study for advancing the field and giving new possibilities to those who need them most.”
Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas.
Authors: Breelyn A. Wilky, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023